Opendata, web and dolomites

SAFEIMMUNOSUPPRESS

Development of immunosuppressive treatments with better safety

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SAFEIMMUNOSUPPRESS" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

The idea of the proposal is to prove the relevance of the development a novel class of immunosuppressive drugs with a better safety. These agents will aim at selectively inhibit the proliferation of T (and B) lymphocytes by targeting a medically relevant target (named CTPS1) recently identified by Dr Latour in the team of Pr Fischer. Proliferation of T lymphocytes is a normal component of the immune reaction toward an antigen, but in certain circumstances, the proliferation of activated T lymphocytes is deleterious including in the context of organ transplantation, autoimmune and inflammatory diseases. Accordingly, several classes of immunosuppressive agents have been developed to inhibit and control these excessive and pathological responses. Actually, most of these inhibitors known are associated with toxicity due to their nonspecific broad effects. A promising future application of immunosuppressive drugs is to search for agents that inhibit unwanted lymphocyte responses by novel and more specific mechanisms. The aim of the project is to conduct a feasibility study for the development of such drugs that could selectively inhibit the proliferation of activated lymphocytes by targeting CTPS1 (without broad side effects as currently used inhibitors). The excepted outcomes of the project are to amass the weight of data needed for achieving a technology transfer to an industrial partner active in drug discovery. These data represent key points to address needed for advancement of the idea to high throughput drug screening and design stage (that will be realized by the industrial partner). This background work includes pre-clinical studies in cellular and animal models and a technical feasibility study validating the plan for drug discovery, as well as IPR finalization, contacts with potential industrial partners and finalization of the commercialization strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFEIMMUNOSUPPRESS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFEIMMUNOSUPPRESS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More